Gamaleya Releases AI-Assisted Personalized Cancer Vaccine
The Gamaleya Institute in Moscow announced on Wednesday that it produced the first three test batches of an AI-assisted, mRNA-based personalized cancer vaccine using patients' genetic profiles. Preclinical studies reported tumor shrinkage of roughly 60–80% depending on patient characteristics, and the Herzen Institute has secured approvals across diagnostics, mRNA production and administration; the batches remain experimental despite passing quality checks.
Key Points
- 1Produce first three test batches of AI-assisted mRNA cancer vaccine at Gamaleya Institute
- 2Show 60–80% tumor shrinkage in preclinical studies, indicating substantial therapeutic potential
- 3Enable personalized, genotype-guided dosing but remain experimental despite quality approvals for clinical use
Scoring Rationale
Notable official milestone with promising preclinical efficacy, but limited by single-source reporting and experimental status.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems